DelveInsight's latest report reveals a robust pipeline with over 80 companies developing 100+ drug candidates for head and neck cancer, highlighting significant research momentum in this therapeutic area.
Candel Therapeutics is set to report updated overall survival data for CAN-2409 in pancreatic ductal adenocarcinoma and non-small cell lung cancer in Q1 2025.
Candel Therapeutics' CAN-2409, combined with radiation therapy, significantly improved disease-free survival in localized prostate cancer patients in a Phase III trial.
Candel Therapeutics reported a net loss of $10.6 million for Q3 2024, with cash runway extending through Q1 2025, while R&D expenses saw a slight decrease.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.